Intellia disclosed that a patient treated with nexiguran ziclumeran as part of the Phase III MAGNITUDE trial has been hospitalized.

The drug, JSKN003, showed promising early efficacy in colorectal cancer patients in China in a Phase I/II trial.

Novartis will acquire the firm's neuroscience assets. Meanwhile, Avidity will separate and transfer its precision cardiology programs to a subsidiary.

In the small first-in-human study, AB-1002 showed an encouraging safety profile and early signs of efficacy, investigators ...

In the study, researchers molecularly screened nearly 2,000 cancer patients and matched 14 percent into a study arm.

A man with neurofibromas who didn't know he's been clinically diagnosed with NF1, learns he harbors a deeply intronic, likely ...

The registrational trial of AD04 could launch as early as mid-2026, if the company is able to shore up necessary funds or ...

Amid steady Q3 growth, Roche's giredestrant-Afinitor combo extended survival in advanced ER-positive, HER2-negative early breast cancer.

In the histology-centric world of cancer medicine, further work is needed to increase genomic testing rates and educate ...

In two Phase I trials, researchers safely administered CAR T cells to high-grade glioma patients and are exploring ways to ...

The company will hold off on making a regulatory decision until it sees results from another trial testing the drug with ...

In a Phase II trial, 23 percent of patients achieved complete remission plus complete remission with partial hematologic recovery on Revuforj.